Ohmura Hirofumi, Kondo Moe, Uenomachi Masato, Ariyama Hiroshi, Ito Mamoru, Tsuchihashi Kenji, Ayano Masahiro, Niiro Hiroaki, Akashi Koichi, Baba Eishi
Department of Oncology and Social Medicine, Kyushu University Graduate School of Medical Sciences, Fukuoka, Japan.
Department of Medicine and Biosystemic Science, Kyushu University Graduate School of Medical Sciences, Fukuoka, Japan.
Front Oncol. 2023 Oct 5;13:1260818. doi: 10.3389/fonc.2023.1260818. eCollection 2023.
The anti-programmed cell death-1 (PD-1) antibody nivolumab has been shown to significantly prolong the survival of patients with unresectable advanced or recurrent gastric cancer (AGC). However, immune-related adverse events (irAEs), which show different profiles from those of cytotoxic agents or conventional molecular-targeted drugs including tyrosine kinase inhibitors, have been reported. Remitting seronegative symmetrical synovitis with pitting edema (RS3PE) is a rare autoimmune disorder with acute-onset, rheumatoid factor-negative, symmetric synovitis associated with limb edema observed in elderly persons. A case of RS3PE syndrome that developed after administration of nivolumab for advanced gastric cancer is reported. This is the first report of a case of RS3PE syndrome as an irAE caused by nivolumab in a patient with gastric cancer.
抗程序性细胞死亡蛋白1（PD-1）抗体纳武单抗已被证明可显著延长不可切除的晚期或复发性胃癌（AGC）患者的生存期。然而，据报道，免疫相关不良事件（irAE）呈现出与细胞毒性药物或包括酪氨酸激酶抑制剂在内的传统分子靶向药物不同的特征。缓解性血清阴性对称性滑膜炎伴凹陷性水肿（RS3PE）是一种罕见的自身免疫性疾病，起病急，类风湿因子阴性，在老年人中观察到与肢体水肿相关的对称性滑膜炎。本文报告1例晚期胃癌患者在使用纳武单抗后发生RS3PE综合征的病例。这是首例关于纳武单抗导致胃癌患者发生RS3PE综合征作为免疫相关不良事件的报道。
